Rapid Dose Therapeutics (CSE: DOSE; OTCQB: RDTCF), a biotechnology and drug delivery innovation company, is accelerating clinical validation of its proprietary QuickStrip™ oral thin film delivery system through expanded cannabinoid research and a high-profile study supported by the National Football League (NFL).

Independent research led by university investigators is examining the role of naturally produced cannabinoids in pain management, concussion recovery, and neuroprotection in contact sports, highlighting growing institutional interest in cannabinoid therapeutics and sports medicine innovation.

Stocks to Watch Under $1: Ensysce Biosciences (NASDAQ: ENSC), OneMedNet Inc (NASDAQ: ONMD), Veea Inc (NASDAQ: VEEA), TMD Energy Ltd (NYSE: TMDE) and Kartoon Studios (NYSE: TOON) trading actively in early trading now!

In parallel, a clinical study is evaluating the bioavailability of CBD delivered via QuickStrip™ compared to traditional oral formats. The research measures pharmacokinetic data, including CBD plasma concentration and absorption efficiency, to determine whether oral thin film delivery enhances systemic uptake. More than 60% of participant data has been extracted, with enrollment continuing through Q2 2026, alongside real-time and accelerated stability testing.

If clinical data confirm improved absorption and rapid onset, QuickStrip™ could significantly strengthen its positioning within the oral thin film drug delivery market, the CBD clinical research sector, and the broader pharmaceutical and nutraceutical industries. Watch QuickStrip™ Drug Delivery System Video Now!

Management believes QuickStrip™ represents a next-generation patient delivery system designed to disrupt traditional capsules, oils, and tablets by offering rapid, discreet, and controlled dosing. With applications spanning pharmaceutical drug delivery, wellness products, nicotine alternatives, and cannabinoid therapeutics, the platform is being positioned as a scalable solution capable of reshaping how active ingredients are administered in both medical and consumer markets.

For investors searching “CSE biotech stocks,” “OTCQB life sciences companies,” “oral thin film delivery technology,” and “CBD clinical trial stocks,” Rapid Dose Therapeutics continues to build a data-driven case for platform validation and long-term growth.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com